老年弥漫大B细胞淋巴瘤联合化疗效果分析
来源:岁月联盟
时间:2017-02-28
参 考 文 献
[1]Vose JM,Link BK,Grossbard ML,et al.Phase Ⅱ study of rituximab in combination with CHOP chemotherapy in patients with previously untreated,aggressive non-Hodgkin’s lymphoma.J Clin Oncol,2001,19(2):389-397.
[2]Coiffier B,Lepage E,Briere J,et al.CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.N Engl J Med,2002,346(4):235-242.
[3]Sehn LH,Jane DJ,Chhanabhai M,et al.Introduction of combined CHOP plus rituximab therapy improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol,2005,23:5027.
[4]Pfreundschuch M,Truemper L,Gill D,et al.Fist analysis of the completed mabthera international (Mlnt)trial in young patients with low-risk diffuse large B-cell lymphoma(DLBCL):Addition of rituximab to a CHOP-like regimens significantly improves outcome of all patients with the identification of a very favorable subgroup with IPI=0 and no bulky disease. Blood,2004,104:Abstract 157.
[5]林桐榆.中山大学肿瘤防治中心,高危弥漫大B细胞淋巴瘤的诊断和治疗进展.肿瘤预防与治疗,2008(1): 1-7.
[6]周立强.中国协和医科大学,肿瘤医院.临床肿瘤学进展,2006,3(2):907-910.
[7]Demidem A,Lam T,Alas S,et al.Chimeric anti-CD20(IDEC-C2B8)monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytoxic drugs.Cancer Biother Radiopharm,1997,12(3):117-186.
[8]Forer A,Lobuglio AF.History of antibody therapy for non-Hodgkin’s lymphoma.Semin Oncol,2003,30(6 Suppl 17):1-5.
[9]Coiffer B,Hiaoun C,Ketterer N,et al. Rituximab (anti-CD20 monoclonal antibody)for the treatment of patients with relapsing or refractory aggressive lymphoma:multicenter phase Ⅱ study.Blood,1998,92(6):1927-1932.